Mono-p-toluenesulfonate salts of AXL kinase inhibitors and their crystalline forms
Patent Information
- Application Number
- JP2024531383
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-26
- Filing Date
- 2022-11-25
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 2024543921000042 
Figure 2024543921000043 
Figure 2024543921000044
Abstract
Description
[Technical field]
[0001] The present invention belongs to the field of pharmaceutical technology. The compound is an AXL kinase inhibitor, and particularly relates to a p-toluenesulfonate salt of the AXL inhibitor and its crystalline form. [Background technology]
[0002] Receptor tyrosine kinases (RTKs) are multi-domain transmembrane proteins that act as sensors of extracellular ligands. Ligand binding to the receptor induces receptor dimerization and activates the intracellular kinase structural domain, resulting in the recruitment, phosphorylation, and activation of multiple downstream signaling cascade reactions (Robinson, DR et al, Oncogene, 19: 5548-5557, 2000). To date, 58 RTKs have been identified in the human genome that control various cellular processes, including cell survival, growth, differentiation, proliferation, adhesion, and motility (Segaliny, AI et al, J. Bone Oncol, 4: 1-12, 2015).
[0003] AXL (also known as UFO, ARK, and Tyro7) belongs to the TAM family of receptor tyrosine kinases, which also includes Mer and Tyro3. Of these, AXL and Tyro3 share the most similar gene structure, and AXL and Mer share the most similar amino acid sequence in the tyrosine kinase domain. Similar to other receptor tyrosine kinases (RTKs), the structure of the TAM family contains an extracellular domain, a transmembrane domain, and a conserved intracellular kinase domain. The extracellular domain of AXL has a unique structure that juxtaposes immunoglobulin and fibronectin type III repeats, reminiscent of the structure of neutrophil adhesion molecule. Members of the TAM family share a common ligand, growth suppression specific protein 6 (Gas6), which binds to all TAM receptor tyrosine kinases. Binding of AXL to Gas6 induces receptor dimerization and autophosphorylation of AXL, activating multiple downstream signaling pathways and contributing to multiple processes in tumor development (Linger, RM et al, Ther. Targets, 14(10), 1073-1090, 2010; Rescigno, J. et al, Oncogene, 6(10), 1909-1913, 1991).
[0004] AXL is widely expressed in normal human tissues, including monocytes, macrophages, platelets, endothelial cells, cerebellum, heart, skeletal muscle, liver and kidney, with the highest expression in cardiac and skeletal muscles, relatively high expression in bone marrow CD34+ cells and stromal cells, and very low expression in normal lymphoid tissues (Wu YM, Robinson DR, Kung HJ, Cancer Res, 64(20), 7311-7320, 2004; Hung BI et al, DNA Cell Biol, 22(8), 533-540, 2003). Studies of many cancer cells have revealed that the AXL gene is overexpressed or ectopically expressed in hematopoietic cells, mesenchymal cells and endothelial cells. Overexpression of AXL kinase is particularly prominent in various types of leukemia and many solid tumors. Inhibition of the AXL receptor tyrosine kinase can reduce pro-survival signals in tumor cells, block tumor invasiveness and enhance the sensitivity to targeted drug therapy and chemotherapy. Therefore, the search for effective AXL inhibitors is an important direction in current tumor-targeting drug research and development. Summary of the Invention
[0005] On the other hand, the present invention provides a mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide or a hydrate thereof.
[0006] Furthermore, the mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide or its hydrate according to the present invention has a specific structure as shown in formula I. [ka]
[0007] Here, X=0 to 2.
[0008] Furthermore, X=0 to 1 or 1.5.
[0009] Further, X is 0, 0.25, 0.5, 0.7, 1, 1.25, 1.5, or 1.75.
[0010] In some exemplary embodiments, X is 0.
[0011] In some exemplary embodiments, X is 0.7.
[0012] In some exemplary embodiments, X is 1.
[0013] In some exemplary embodiments, X is 1.5.
[0014] The present invention further provides a hydrate of the mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide.
[0015] In some exemplary embodiments, the present invention provides (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide mono-p-toluenesulfonate monohydrate, having the specific structure shown in formula II: [ka]
[0016] In some exemplary embodiments, the present invention provides (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide mono-p-toluenesulfonate sesquihydrate, having the specific structure shown in formula III: [ka]
[0017] The present invention further provides a crystalline form of the mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide, or a hydrate thereof.
[0018] The present invention further provides a crystalline form of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide mono-p-toluenesulfonate or a hydrate thereof, which has diffraction peaks at 2θ (diffraction angle) of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 13.2°±0.2° and 21.8°±0.2° in its powder X-ray diffraction graph.
[0019] In some exemplary embodiments, the crystal has diffraction peaks at 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 21.8°±0.2°, and 22.6°±0.2° 2θ in its powder X-ray diffraction graph.
[0020] In some exemplary embodiments, the crystal has diffraction peaks at 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 18.7°±0.2°, 19.4°±0.2°, 19.7°±0.2°, 21.8°±0.2°, 22.6°±0.2°, and 29.4°±0.2° 2θ in its X-ray powder diffraction graph.
[0021] In some more exemplary embodiments, the crystal has an X-ray powder diffraction pattern with 2θ values of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 12.3°±0.2°, 12.4°±0.2°, 12.6°±0.2°, 13.2°±0.2°, 14.1°±0.2°, 15.2°±0.2°, 15.9°±0.2°, 16.7°±0.2°, 17.1°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 18.7°±0.2°, 19.0°±0.2°, 19.4°±0.2°, 19.6°±0.2°, 19.8 ... It has diffraction peaks at 9.7°±0.2°, 21.1°±0.2°, 21.8°±0.2°, 22.6°±0.2°, 23.3°±0.2°, 23.7°±0.2°, 24.1°±0.2°, 24.4°±0.2°, 24.7°±0.2°, 25.1°±0.2°, 26.2°±0.2°, 26.6°±0.2°, 27.0°±0.2°, 27.7°±0.2°, 28.0°±0.2°, 28.3°±0.2°, 28.7°±0.2°, 28.8°±0.2°, 29.4°±0.2°, 30.2°±0.2° and 33.9°±0.2°.
[0022] In some embodiments, the crystal has a heat absorption peak at an onset temperature of 195±5° C. to 205±5° C. in a calorimetry chart measured by differential scanning calorimetry.
[0023] In some embodiments, the crystal has a heat absorption peak at an onset temperature of 198±5° C. to 203±5° C. in a calorimetry chart measured by differential scanning calorimetry.
[0024] In some embodiments, the crystal has a heat absorption peak at an onset temperature of 200±5° C. in a calorimetry chart measured by differential scanning calorimetry.
[0025] The present invention further provides a crystalline form of the compound of formula I, wherein X=0-1, having diffraction peaks at 2θ of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 13.2°±0.2° and 21.8°±0.2° in its powder X-ray diffraction graph.
[0026] In some exemplary embodiments, the crystal has diffraction peaks at 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 21.8°±0.2°, and 22.6°±0.2° 2θ in its powder X-ray diffraction graph.
[0027] In some exemplary embodiments, the crystal has diffraction peaks at 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 18.7°±0.2°, 19.4°±0.2°, 19.7°±0.2°, 21.8°±0.2°, 22.6°±0.2°, and 29.4°±0.2° 2θ in its X-ray powder diffraction graph.
[0028] In some more exemplary embodiments, the crystal has an X-ray powder diffraction pattern with 2θ values of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 12.3°±0.2°, 12.4°±0.2°, 12.6°±0.2°, 13.2°±0.2°, 14.1°±0.2°, 15.2°±0.2°, 15.9°±0.2°, 16.7°±0.2°, 17.1°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 18.7°±0.2°, 19.0°±0.2°, 19.4°±0.2°, 19.6°±0.2°, 19.8 ... It has diffraction peaks at 9.7°±0.2°, 21.1°±0.2°, 21.8°±0.2°, 22.6°±0.2°, 23.3°±0.2°, 23.7°±0.2°, 24.1°±0.2°, 24.4°±0.2°, 24.7°±0.2°, 25.1°±0.2°, 26.2°±0.2°, 26.6°±0.2°, 27.0°±0.2°, 27.7°±0.2°, 28.0°±0.2°, 28.3°±0.2°, 28.7°±0.2°, 28.8°±0.2°, 29.4°±0.2°, 30.2°±0.2° and 33.9°±0.2°.
[0029] In some embodiments, the crystal has a heat absorption peak at an onset temperature of 195±5° C. to 205±5° C. in a calorimetry chart measured by differential scanning calorimetry.
[0030] In some embodiments, the crystals have a heat absorption peak at an onset temperature of 198±5° C. to 203±5° C. in a calorimetry chart measured by differential scanning calorimetry.
[0031] In some more exemplary embodiments, the crystals have a heat absorption peak at an onset temperature of 200±5° C. in a calorimetry chart measured by differential scanning calorimetry.
[0032] The present invention further provides a crystalline form B of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide mono-p-toluenesulfonate monohydrate, having diffraction peaks at 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 13.2°±0.2° and 21.8°±0.2° 2θ in its X-ray powder diffraction pattern.
[0033] In some embodiments, the crystalline form B has diffraction peaks at the following angles 2θ: 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 21.8°±0.2°, and 22.6°±0.2° in its powder X-ray diffraction graph.
[0034] In some embodiments, the crystalline form B has diffraction peaks at the following angles 2θ: 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 18.7°±0.2°, 19.4°±0.2°, 19.7°±0.2°, 21.8°±0.2°, 22.6°±0.2°, and 29.4°±0.2° in its X-ray powder diffraction graph.
[0035] In some embodiments, the crystalline form B has an X-ray powder diffraction pattern with 2θ values of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 12.3°±0.2°, 12.4°±0.2°, 12.6°±0.2°, 13.2°±0.2°, 14.1°±0.2°, 15.2°±0.2°, 15.9°±0.2°, 16.7°±0.2°, 17.1°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 18.7°±0.2°, 19.0°±0.2°, 19.4°±0.2°, 19.6°±0.2°, 19.8 ... The diffraction peaks are at 7°±0.2°, 21.1°±0.2°, 21.8°±0.2°, 22.6°±0.2°, 23.3°±0.2°, 23.7°±0.2°, 24.1°±0.2°, 24.4°±0.2°, 24.7°±0.2°, 25.1°±0.2°, 26.2°±0.2°, 26.6°±0.2°, 27.0°±0.2°, 27.7°±0.2°, 28.0°±0.2°, 28.3°±0.2°, 28.7°±0.2°, 28.8°±0.2°, 29.4°±0.2°, 30.2°±0.2° and 33.9°±0.2°.
[0036] In some more exemplary embodiments, the powder X-ray diffraction of said crystalline form B expressed in 2θ angles has the data set forth in the table below. [Table 1-1] [Table 1-2]
[0037] In some embodiments, the powder X-ray diffraction of the crystalline form B expressed in 2θ angles has a graph as shown in FIG.
[0038] In some embodiments, the crystalline form B has a heat absorption peak at an onset temperature of 85±5° C. to 95±5° C. and a heat absorption peak at an onset temperature of 195±5° C. to 205±5° C. in a calorimetry chart measured by differential scanning calorimetry.
[0039] In some embodiments, the crystalline form B has a heat absorption peak at an onset temperature of 88±5° C. to 93±5° C., and a heat absorption peak at an onset temperature of 198±5° C. to 203±5° C., in a calorimetry chart measured by differential scanning calorimetry.
[0040] In some embodiments, the crystalline form B has a heat absorption peak at an onset temperature of 90±5° C. and a heat absorption peak at an onset temperature of 200±5° C. in a calorimetry chart measured by differential scanning calorimetry.
[0041] In some embodiments, the crystalline form B has a calorimetry chart as shown in FIG. 2, as measured by differential scanning calorimetry.
[0042] In some embodiments, the crystalline form B has a wavelength (cm) of 1.0 or less in a spectrum measured by Fourier transform attenuated total reflectance infrared spectroscopy. -1 ), the following absorption bands: 432±2, 471±2, 552±2, 570±2, 711±2, 747±2, 779±2, 818±2, 836±2, 863±2, 932±2, 966±2, 1295±2, 1318±2, 2635±2, 2721±2, 2927±2, 3005±2, 3110±2, 3185±2, 3256±2 and 3556±2.
[0043] In some embodiments, the crystalline form B has a wavelength (cm) of 1.0 or less in a spectrum measured by Fourier transform attenuated total reflectance infrared spectroscopy. -1) has the following absorption bands: 432±2, 471±2, 497±2, 552±2, 570±2, 681±2, 711±2, 747±2, 779±2, 818±2, 836±2, 863±2, 932±2, 966±2, 1008±2, 1030±2, 1096±2, 1121±2, 1159±2, 1229±2, 1295±2, 1318±2, 1374±2, 1413±2, 1456±2, 1512±2, 1527±2, 1571±2, 1609±2, 2635±2, 2721±2, 2927±2, 3005±2, 3110±2, 3185±2, 3256±2 and 3556±2.
[0044] In some embodiments, the crystalline form B has a spectrum measured by Fourier transform Raman spectroscopy with a wavelength (cm -1 ) have the following absorption bands, which are expressed as the reciprocal of the absorption bands: 1609±2, 1572±2, 1553±2, 1535±2, 1508±2, 1494±2, 1476±2, 1457±2, 1420±2, 1374±2, 1344±2, 1331±2, 1285±2, 1262±2, 1228±2, 1213±2, 1173±2, 1147±2, 1135±2, 1099±2, 1059±2, 1029±2, 1115±2, 1006 ±2, 970±2, 965±2, 819±2, 799±2, 744±2, 733±2, 678±2, 658±2, 634±2, 613±2, 570±2, 534±2, 497±2, 471±2, 448±2, 425±2, 393±2, 369±2, 313±2, 287±2, 262±2, 241±2, 217±2, 177±2, 156±2, 104±2 and 82±2.
[0045] In some embodiments, the crystalline form B loses 2.4% of its weight over the temperature range of 25°C to 150°C.
[0046] In some embodiments, the crystalline form B has a TGA graph as shown in FIG.
[0047] In some more exemplary embodiments, the crystalline form B has single crystal crystal parameters and structural data as set forth in the table below. [Table 2]
[0048] Furthermore, the present invention provides crystalline form C of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide mono-p-toluenesulfonate sesquihydrate having the specific structure shown in formula III. [ka]
[0049] In its powder X-ray diffraction graph, it has diffraction peaks at 2θ of 13.4°±0.2°, 18.4°±0.2°, 19.3°±0.2°, 19.8°±0.2° and 21.8°±0.2°.
[0050] In some embodiments, the crystalline form C has diffraction peaks at the following angles 2θ: 12.1°±0.2°, 13.4°±0.2°, 15.0°±0.2°, 16.9°±0.2°, 18.4°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 21.8°±0.2°, 23.6°±0.2°, and 24.3°±0.2° in its X-ray powder diffraction graph.
[0051] In some embodiments, the crystalline form C has diffraction peaks at the following angles 2θ: 6.0°±0.2°, 10.8°±0.2°, 12.1°±0.2°, 13.4°±0.2°, 15.0°±0.2°, 16.9°±0.2°, 18.4°±0.2°, 19.0°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 20.9°±0.2°, 21.8°±0.2°, 23.2°±0.2°, 23.6°±0.2°, 24.3°±0.2°, 25.5°±0.2°, and 26.6°±0.2° in its X-ray powder diffraction graph.
[0052] In some more exemplary embodiments, the crystalline form C has an X-ray powder diffraction pattern 2θ detailed in the table below. [Table 3]
[0053] In some embodiments, the powder X-ray diffraction of the crystalline form C expressed in 2θ angles has a graph as shown in FIG.
[0054] In some more exemplary embodiments, the crystalline form C has single crystal crystal parameters and structural data as set forth in the table below. [Table 4]
[0055] Meanwhile, the present invention provides crystalline form A of compound of formula IV, which in its powder X-ray diffraction pattern has diffraction peaks at 2θ degrees of 7.6±0.2°, 10.2°±0.2°, 17.6°±0.2°, 20.3°±0.2° and 20.9±0.2°. [ka]
[0056] In some embodiments, the crystalline form A has diffraction peaks at degrees 2θ of 4.1±0.2°, 7.6°±0.2°, 10.2°±0.2°, 12.6°±0.2°, 13.0°±0.2°, 17.6°±0.2°, 19.7°±0.2°, 20.3°±0.2°, 20.9°±0.2° and 22.2±0.2° in its powder X-ray diffraction graph.
[0057] In some embodiments, the crystalline form A has diffraction peaks at degrees 2θ of 4.1±0.2°, 5.6°±0.2°, 7.6°±0.2°, 10.2°±0.2°, 10.9°±0.2°, 12.6°±0.2°, 13.0°±0.2°, 15.2°±0.2°, 17.6°±0.2°, 19.7°±0.2°, 20.3°±0.2°, 20.9°±0.2°, 22.2°±0.2°, 23.2°±0.2°, 24.6°±0.2°, 27.0°±0.2°, 28.8°±0.2°, 37.0°±0.2°, and 37.7±0.2° in its powder X-ray diffraction graph.
[0058] In some more exemplary embodiments, the crystalline form A has an X-ray powder diffraction pattern 2θ detailed in the table below. [Table 5]
[0059] In some more exemplary embodiments, the X-ray powder diffraction of said crystalline form A, expressed in 2θ angles, has a graph as shown in FIG.
[0060] Meanwhile, the present invention provides a process for preparing the mono-p-toluenesulfonic acid salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide, or a pharma- ceutically acceptable hydrate thereof, comprising the step of forming a salt of a compound of formula IV with p-toluenesulfonic acid.
[0061] On the other hand, the present invention provides a process for preparing the compound of formula I or a crystalline form thereof, which comprises the step of forming a salt of the compound of formula IV with p-toluenesulfonic acid.
[0062] In some embodiments, the crystalline form of the compound of formula I can be prepared by the methods of suspension stirring, gas-solid diffusion, solvent evaporation, or temperature-reduced crystallization.
[0063] Meanwhile, the present invention provides a method for preparing crystalline form B, which comprises reacting the compound of formula IV with p-toluenesulfonic acid monohydrate in an alcohol solvent, and precipitating the crystals in an anti-solvent.
[0064] In some embodiments, the alcohol solvent may be an alcohol solvent or a mixture of alcohol and water, and the alcohol solvent is one selected from methanol, ethanol, isopropanol, etc., and is preferably ethanol or isopropanol.
[0065] In some embodiments, the anti-solvent is selected from an ester solvent, a ketone solvent or an ether solvent, the ketone solvent being acetone, 2-butanone or methyl isobutyl ketone, preferably acetone, the ether solvent being methyl tert-butyl ether or 1,4-dioxane, preferably methyl tert-butyl ether, and the ester solvent being selected from ethyl acetate, butyl acetate or isopropyl acetate, preferably isopropyl acetate.
[0066] On the other hand, the present invention provides a pharmaceutical composition comprising the mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide or a hydrate thereof.
[0067] The present invention also provides a pharmaceutical composition comprising a compound of formula I.
[0068] On the other hand, the present invention provides a pharmaceutical composition comprising a compound of formula II.
[0069] On the other hand, the present invention provides a pharmaceutical composition comprising a compound of formula III.
[0070] In some embodiments, the pharmaceutical composition further comprises one or more pharma- ceutically acceptable carriers.
[0071] In some embodiments, the pharmaceutical composition is a solid pharmaceutical formulation suitable for oral administration, preferably a tablet or capsule.
[0072] Meanwhile, the present invention provides a crystalline composition comprising crystalline form A, wherein said crystalline form A accounts for 50% by weight or more of the weight of the crystalline composition, preferably 80% by weight or more, more preferably 90% by weight or more, even more preferably 95% by weight or more, and most preferably 98% by weight or more.
[0073] Meanwhile, the present invention further provides a pharmaceutical composition comprising said crystalline form A or a crystalline form composition thereof.
[0074] In some embodiments, the pharmaceutical composition further comprises one or more pharma- ceutically acceptable carriers.
[0075] In some embodiments, the pharmaceutical composition is a solid pharmaceutical formulation suitable for oral administration, preferably a tablet or capsule.
[0076] Meanwhile, the present invention provides a crystalline composition comprising crystalline form B, wherein said crystalline form B accounts for 50% by weight or more of the weight of the crystalline composition, preferably 80% by weight or more, more preferably 90% by weight or more, even more preferably 95% by weight or more, and most preferably 98% by weight or more.
[0077] Meanwhile, the present invention further provides a pharmaceutical composition comprising said crystalline form B or a crystalline form composition thereof.
[0078] In some embodiments, the pharmaceutical composition further comprises one or more pharma- ceutically acceptable carriers.
[0079] In some embodiments, the pharmaceutical composition is a solid pharmaceutical formulation suitable for oral administration, preferably a tablet or capsule.
[0080] Meanwhile, the present invention provides a crystalline composition comprising crystalline form C, wherein said crystalline form B accounts for 50% by weight or more of the weight of the crystalline composition, preferably 80% by weight or more, more preferably 90% by weight or more, even more preferably 95% by weight or more, and most preferably 98% by weight or more.
[0081] Meanwhile, the present invention further provides a pharmaceutical composition comprising said crystalline form C or a composition of said crystalline form C.
[0082] In some embodiments, the pharmaceutical composition further comprises one or more pharma- ceutically acceptable carriers.
[0083] In some embodiments, the pharmaceutical composition is a solid pharmaceutical formulation suitable for oral administration, preferably a tablet or capsule.
[0084] Meanwhile, the present invention further provides a compound of formula I or a pharmaceutical composition thereof for use as a medicament.
[0085] Meanwhile, the present invention further provides a compound of formula II or a pharmaceutical composition thereof for use as a medicament.
[0086] Meanwhile, the present invention further provides a compound of formula III or a pharmaceutical composition thereof for use as a medicament.
[0087] Meanwhile, the present invention further provides crystalline form A, a crystalline form composition thereof, or a pharmaceutical composition thereof for use as a medicament.
[0088] Meanwhile, the present invention also further provides crystalline form B, a crystalline form composition thereof, or a pharmaceutical composition thereof for use as a medicament.
[0089] Meanwhile, the present invention further provides crystalline form C, a crystalline form composition thereof, or a pharmaceutical composition thereof for use as a medicament.
[0090] Meanwhile, the present invention further provides the use of the mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide, its hydrate, and pharmaceutical compositions thereof in the preparation of a medicament for the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0091] Meanwhile, the present invention further provides the use of said compound of formula I or a pharmaceutical composition thereof in the preparation of a medicament for the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0092] Meanwhile, the present invention further provides the use of said compound of formula II or a pharmaceutical composition thereof in the preparation of a medicament for the prevention and / or treatment of a disease or pathology mediated by AXL kinase.
[0093] Meanwhile, the present invention further provides the use of said compound of formula III or a pharmaceutical composition thereof in the preparation of a medicament for the prevention and / or treatment of a disease or pathology mediated by AXL kinase.
[0094] Meanwhile, the present invention further provides the use of said crystalline form A or a pharmaceutical composition thereof in the preparation of a medicament for the prevention and / or treatment of a disease or pathology mediated by AXL kinase.
[0095] Meanwhile, the present invention further provides the use of said crystalline form B or a pharmaceutical composition thereof in the preparation of a medicament for the prevention and / or treatment of a disease or pathology mediated by AXL kinase.
[0096] Meanwhile, the present invention further provides the use of said crystalline form C or a pharmaceutical composition thereof in the preparation of a medicament for the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0097] Meanwhile, the present invention further provides the use of the mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide, or a hydrate thereof, in the preparation of a medicament for the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0098] Meanwhile, the present invention further provides the use of said compound of formula I in the preparation of a medicament for the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0099] Meanwhile, the present invention further provides the use of said compound of formula II in the preparation of a medicament for the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0100] Meanwhile, the present invention further provides the use of said compound of formula III in the preparation of a medicament for the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0101] Meanwhile, the present invention further provides the use of said crystalline form composition in the preparation of a medicament for the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0102] Meanwhile, the present invention further provides the use of said crystalline form A, a crystalline form composition thereof, or a pharmaceutical composition thereof in the preparation of a medicament for the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0103] Meanwhile, the present invention further provides the use of said crystalline form B, a crystalline form composition thereof, or a pharmaceutical composition thereof in the preparation of a medicament for the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0104] Meanwhile, the present invention further provides the use of said crystalline form C, a crystalline form composition thereof, or a pharmaceutical composition thereof in the preparation of a medicament for the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0105] Meanwhile, the present invention further provides a method for preventing and / or treating a disease or condition mediated by AXL kinase, comprising administering the mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide of the present invention, a hydrate thereof, or a pharmaceutical composition thereof to an individual in need thereof.
[0106] Meanwhile, the present invention further provides a method for preventing and / or treating a disease or condition mediated by AXL kinase, comprising administering the compound of formula I of the present invention or a pharmaceutical composition thereof to an individual in need thereof.
[0107] Meanwhile, the present invention further provides a method for preventing and / or treating a disease or condition mediated by AXL kinase, comprising administering the compound of formula II of the present invention or a pharmaceutical composition thereof to an individual in need thereof.
[0108] Meanwhile, the present invention further provides a method for preventing and / or treating a disease or condition mediated by AXL kinase, comprising administering the compound of formula III of the present invention or a pharmaceutical composition thereof to an individual in need thereof.
[0109] Meanwhile, the present invention further provides a method for preventing and / or treating a disease or condition mediated by AXL kinase, comprising administering the crystalline form composition of the present invention to an individual in need thereof.
[0110] Meanwhile, the present invention further provides a method for preventing and / or treating a disease or condition mediated by AXL kinase, comprising administering the crystalline form A of the present invention or a pharmaceutical composition thereof to an individual in need thereof.
[0111] Meanwhile, the present invention further provides a method for preventing and / or treating a disease or condition mediated by AXL kinase, comprising administering the crystalline form B of the present invention or a pharmaceutical composition thereof to an individual in need thereof.
[0112] Meanwhile, the present invention further provides a method for preventing and / or treating a disease or condition mediated by AXL kinase, comprising administering the crystalline form C of the present invention or a pharmaceutical composition thereof to an individual in need thereof.
[0113] Meanwhile, the present invention provides the mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide of the present invention, or a hydrate thereof, for use in the prevention and / or treatment of a disease or pathology mediated by AXL kinase.
[0114] Meanwhile, the present invention further provides the said compounds of formula I of the present invention for use in the prevention and / or treatment of a disease or pathology mediated by AXL kinase.
[0115] Meanwhile, the present invention further provides the said compound of formula II of the present invention for use in the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0116] Meanwhile, the present invention further provides the said compound of formula III of the present invention for use in the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0117] Meanwhile, the present invention further provides the crystalline form composition of the present invention for use in the prevention and / or treatment of a disease or condition mediated by AXL kinase.
[0118] Meanwhile, the present invention further provides said crystalline form A of the present invention or a pharmaceutical composition thereof for use in the prevention and / or treatment of a disease or pathology mediated by AXL kinase.
[0119] Meanwhile, the present invention further provides said crystalline form B of the present invention or a pharmaceutical composition thereof for use in the prevention and / or treatment of a disease or pathology mediated by AXL kinase.
[0120] Meanwhile, the present invention further provides said crystalline form C of the present invention or a pharmaceutical composition thereof for use in the prevention and / or treatment of a disease or pathology mediated by AXL kinase.
[0121] In some embodiments, the AXL kinase-mediated disease or condition is cancer.
[0122] In some exemplary embodiments, the cancer is associated with a hematological malignancy.
[0123] The mono-p-toluenesulfonate salt of compound of formula IV, its hydrate and the crystal form of the hydrate prepared by the present invention have good stability, solving the problem of instability of the free base (compound of formula IV) under high temperature, high humidity and light conditions, and the crystal form obtained by the preparation has the advantages of stability, easy processing and high solubility.
[0124] definition Unless otherwise stated, the following terms used in the specification and claims have the meanings set forth below.
[0125] The term "pharmaceutical acceptable carrier" refers to a carrier that does not cause significant irritation to the body and does not impair the biological activity and properties of the active compound. This includes, but is not limited to, diluents, disintegrants, binders, flow aids, wetting agents, etc., approved by the US Food and Drug Administration for use in humans or animals.
[0126] The "powder X-ray diffraction graph" in the present invention is obtained by measurement using Cu-Kα radiation.
[0127] In the present invention, "2θ" or "2θ angle" means the diffraction angle, where θ is the Bragg angle (unit is "°" or "degree"), and the error range of 2θ of each characteristic peak is ±0.20°.
[0128] In addition, in powder X-ray diffraction spectra (XRPD), the diffraction spectrum obtained from a crystalline compound tends to be characteristic of a particular crystal, and the relative intensity of bands (especially at low angles) may change due to dominant orientation effects resulting from differences in crystallization conditions, particle size, and other measurement conditions. Therefore, the relative intensity of the diffraction peaks is not characteristic of the crystal of interest. It is the relative position of the peaks, rather than their relative intensity, that should be considered when determining whether a crystal is identical to a known one. Furthermore, in the field of crystallography, it is well known that there is a slight error in the position of the peaks in any crystal. For example, the position of the peaks may move due to temperature changes when analyzing the sample, movement of the sample, calibration of the instrument, etc., and the measurement error of the 2θ value may be about ±0.2°. Therefore, this error must be taken into account when determining each crystal structure. In XRPD graphs, the peak positions are usually expressed as 2θ angles or interplanar spacing d, and there is a simple conversion relationship between the two: d=λ / (2sinθ), where d is the interplanar spacing, λ is the wavelength of the incident X-rays, and θ is the diffraction angle. For the same crystal of the same compound, the peak positions in the XRPD spectrum are generally similar, and the error in the relative intensities may be large. In addition, in the identification of a mixture, some diffraction lines may be missing due to factors such as a decrease in content, and in this case, it is not necessary to rely on the full spectrum of bands observed in a high-purity sample; even a single spectral band may be characteristic of a certain crystal.
[0129] Differential scanning calorimetry (DSC) measures the transition temperatures at which crystals absorb or release heat as a result of changes in crystal structure or crystalline melting. For the same crystalline form of the same compound, the thermal transition temperatures and melting points are typically within about 5°C, usually within about 3°C, in successive analyses. When a compound is described as having a DSC peak or melting point, it refers to the DSC peak or melting point ±5°C. DSC provides an auxiliary method for identifying various crystalline forms. Different crystalline forms can be recognized based on different transition temperature characteristics. However, for mixtures, the DSC peak or melting point may vary over a wider range. Furthermore, the melting temperature is related to the rate of heating, since decomposition occurs as the substance melts.
[0130] Thermogravimetric analysis (TGA) refers to a thermal analysis technique that measures the relationship between the mass of a sample and the temperature change at a program-controlled temperature. When the substance being measured sublimes or vaporizes during the heating process, decomposition into gas or loss of water of crystallization occurs, causing a change in the mass of the substance being measured. In this case, it is observed that the thermogravimetric curve is not linear, but decreases. By analyzing the thermogravimetric curve, it is possible to know at what temperature the substance being measured changed, and by the weight lost, it is possible to calculate how much substance was lost.
[0131] For example, when referring to an XRPD graph, a DSC graph, or a TGA graph, the term "as shown in ..." includes graphs that are not necessarily identical to those depicted herein, but that fall within experimental error as considered by one of ordinary skill in the art.
[0132] As used herein, the term "hydrate" refers to a specific solvate where the solvent is water; examples of hydrates include hemihydrate, monohydrate, sesquihydrate, dihydrate, and the like.
[0133] Different crystalline forms of a particular substance, such as a salt of the invention, may include both anhydrous forms of the substance and hydrated forms of the substance, each of which is distinguished from the other by a different XRPD image and thus a different crystal lattice. In some instances, a single crystalline form (e.g., identified by separate XRPD images) may have variable water or solvent content, but the crystal lattice is essentially unchanged except for compositional changes with respect to water and / or solvent (as represented by the XRPD image).
[0134] Unless otherwise specified, the abbreviations used in the present invention have the following meanings. M:mol / L mM:mmol / L nM:nmol / L Boc: tert-butoxycarbonyl 1 HNMR: Nuclear magnetic resonance hydrogen spectroscopy MS(ESI+):Mass spectrometry DMSO-d6: Deuterated dimethyl sulfoxide CDCl3: Deuterated chloroform DTT: Dithiothreitol SEB: Supplemented Enzymatic Buffer IMDM (Iscove's Modified Dulbecco's Medium): Iscove's modified Dulbecco's medium. Room temperature: 25℃. [Brief description of the drawings]
[0135] In order to more clearly describe the embodiments of the present invention and the technical solutions of the prior art, the following briefly introduces the accompanying drawings that need to be used in the embodiments of the present invention and the prior art. However, it is obvious that the accompanying drawings in the following description are only part of the embodiments of the present invention, and those skilled in the art can obtain other accompanying drawings according to these drawings. [Figure 1] 1 is a powder X-ray diffraction (XRPD) spectrum of crystalline form B of Example 3. [Diagram 2] 1 is a differential scanning calorimetry (DSC) spectrum of crystalline form B of Example 3. [Diagram 3] 1 is a thermogravimetric (TGA) spectrum of crystalline form B of Example 3. [Figure 4] 1 is an FT-IR spectrum of crystalline form B of Example 3. [Diagram 5] 1 is an FT-Raman spectrum of crystalline form B of Example 3. [Figure 6] 1 is a dynamic moisture sorption (DVS) spectrum of crystalline form B of Example 3. [Figure 7] 1 is a powder X-ray diffraction (XRPD) spectrum of crystalline form C of Example 6. [Figure 8] 1 is a powder X-ray diffraction (XRPD) spectrum of crystalline form A of Example 8. [Figure 9] 1 is an X-ray powder diffraction (XRPD) spectrum of the methanesulfonate salt of the compound of formula IV in Example 10. [Figure 10] 1 is the powder X-ray diffraction (XRPD) spectrum of the monohydrochloride salt of the compound of formula IV of Example 10. [Figure 11] 1 is the powder X-ray diffraction (XRPD) spectrum of the dihydrochloride salt of the compound of formula IV of Example 10. [Figure 12] 1 is an X-ray powder diffraction (XRPD) spectrum of the phosphate salt of compound of formula IV in Example 10. [Figure 13] 1 is an X-ray powder diffraction (XRPD) spectrum of the hippurate salt of compound of formula IV in Example 10. [Figure 14] 1 is an X-ray powder diffraction (XRPD) spectrum of the sulfate salt of the compound of formula IV in Example 10. [Figure 15] 1 is an X-ray powder diffraction (XRPD) spectrum of the hydrobromide salt of the compound of formula IV in Example 10. [Figure 16] 1 is an X-ray powder diffraction (XRPD) spectrum of the benzenesulfonate salt of the compound of formula IV in Example 10. [Figure 17]1 is an X-ray powder diffraction (XRPD) spectrum of the oxalate salt of compound of formula IV in Example 10. [Figure 18] 1 is an X-ray powder diffraction (XRPD) spectrum of the fumarate salt of the compound of formula IV in Example 10. [Figure 19] 1 is an X-ray powder diffraction (XRPD) spectrum of the citrate salt of the compound of formula IV in Example 10. [Figure 20] 1 is a powder X-ray diffraction (XRPD) spectrum of the compound of formula I prepared in Example 11. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0136] The present invention will be described in more detail below through examples. However, these specific descriptions are only intended to illustrate the technical solutions of the present invention, and are not intended to limit the present invention.
[0137] The test conditions for each device are as follows: (1) X-ray Powder Diffraction (XRPD) Model number: Bruker D2 Phaser 2nd [Table 6]
[0138] (2) Thermogravimetric analyzer (TGA) Model number: TA Instruments TGA 25 Purge gas: Nitrogen Heating rate: 10℃ / min Temperature range: Room temperature to 300℃ Method: Place the sample in an aluminum dish, place the dish in a platinum dish, open it in a nitrogen atmosphere, and heat it from room temperature to the set temperature at a heating rate of 10°C / min.
[0139] (3) Differential Scanning Calorimeter (DSC) Model number: TA Instruments DSC 25 Purge gas: Nitrogen Heating rate: 10℃ / min Temperature range: 20 to 300°C Method: Place the sample in an aluminum dish, cover it, and heat it from 20°C to the set temperature at a rate of 10°C / min under a nitrogen atmosphere.
[0140] (4) Fourier transform infrared spectroscopy (FT-IR) Device model number: Thermo Fourier infrared spectrometer ID1-summit Instrument calibration: polystyrene film Measurement conditions: KBr press method
[0141] (5) Fourier transform Raman spectroscopy (FT-Raman) Model number: Nikoli Fourier transform Raman spectrometer DXR780 Exposure time: 20 seconds Number of exposures: 10 Light source: 780nm Slits: 400 / mm Laser power: 14mW Scan range: 50cm -1 ~3000cm -1
[0142] (6) Dynamic moisture sorption (DVS) Device model number: Surface Measurement System (SMS) The specific device setting parameters are as follows: [Table 7]
[0143] (7) Information on single crystal diffractometer and its parameters Single Crystal X-ray Diffraction (SCXRD) Device model number: Bruker D8 Venture Light source: Cu-Kα, λ=1.54Å Detector: CMOS surface detector Resolution: 0.8Å X-ray tube settings: Tube voltage 50KV, tube current 1.2mA Exposure time: 50 seconds Measurement temperature: 170(2)K
[0144] (8) HPLC analysis conditions [Table 8]
[0145] Working Example Example 1: Preparation of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide [ka]
[0146] a) 2-iodo-4-(methoxymethyl)aniline To a dichloromethane (261 mL) / water (135 mL) solution, 4-(methoxymethyl)aniline (9 g), iodine (16.65 g) and sodium bicarbonate (16.53 g) were added and stirred at 22° C. for 16 hours. The reaction solution was quenched with saturated sodium thiosulfate (10 mL) at room temperature. The resulting mixture was extracted with dichloromethane (3×100 mL), and the combined organic layer was then washed with saturated aqueous sodium chloride solution (1×100 mL), and the organic layer was dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1 v / v) to give the title compound (16 g). MS(ESI+): 264.0 (M+H).
[0147] b) (2-amino-5-(methoxymethyl)phenyl)dimethylphosphine oxide To a stirred solution of 2-iodo-4-(methoxymethyl)aniline (16 g, 60.82 mmol, 1.00 eq.), potassium phosphate (14.20 g), palladium acetate (0.68 g) and 4,5-bisdiphenylphosphino-9,9-dimethyloxanthene (1.76 g) in N,N-dimethylformamide (224 mL) under nitrogen atmosphere, dimethylphosphine oxide (5.22 g) was added and stirred at 120° C. for 2 h. The mixture was cooled to room temperature. The resulting mixture was filtered and the filter cake was washed with N,N-dimethylformamide (3×5 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol=20 / 1 v / v) to give the title product (12.9 g). MS(ESI+): 214.1 (M+H).
[0148] c) (2-((2,5-dichloropyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide (2-Amino-5-(methoxymethyl)phenyl)dimethylphosphine oxide (1.10 g), 2,4,5-trichloropyrimidine (1.23 g) and N,N-diisopropylethylamine (2.00 g) were added to N,N-dimethylformamide (22 mL) at room temperature and stirred for 3 hours. The resulting mixture was diluted with dichloromethane (30 mL). The reaction was quenched by adding water (10 mL) at 0° C. The resulting mixture was extracted with dichloromethane (3×50 mL). The combined organic layer was washed with saturated sodium chloride (1×50 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol=20 / 1 v / v) to give the title compound (1.28 g). MS(ESI+): 360.0 (M+H).
[0149] d) (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide (2-((2,5-dichloropyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide (50.00 mg) and (S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-amine (31.98 mg) were added to isopropanol (2 mL), followed by a solution of hydrogen chloride in 1,4-dioxane in water (10 drops, 4 M) and irradiated in a microwave at 130° C. for 3.5 hours. The mixture was then cooled to room temperature and concentrated under reduced pressure. The crude product was purified by reversed-phase high-performance liquid chromatography (column YMC Actus Triart C18, 30×150 mm, particle size 5 μm, mobile phase A: water (10 mmol / L ammonium bicarbonate), mobile phase B: acetonitrile, flow rate: 60 mL / min, gradient: 20% B to 50% B, 8 min, wavelength: 220 nm, retention time: 6.83 min, column temperature: 25° C.) to obtain the title product (20.2 mg).
[0150] 1 HNMR(400MHz,DMSO-d6,ppm)δ11.07(s,1H),9.26(s,1H),8.52(d,J=4.6Hz,1H),8.17(s,1H),7.53(dd,J=14.0,2.0Hz, 1H),7.44(q,J=3.1Hz,2H),7.26(dd,J=8.1,2.3Hz,1H),6.97(d,J=8.1Hz,1H),4.42(s,2H),3.31(s,3H),3.01-2.75(m, 2H),2.55(s,5H),2.50(s,2H),1.84(s,2H),1.81(s,3H),1.77(s,3H),1.70(q,J=3.6,3.2Hz,4H),1.54(s,2H).MS(ESI+):554.2(M+H).
[0151] Example 2: Activity measurement Related enzymatic, cellular and in vivo activities of related compounds prepared in Example 1 The specific structure of the positive drug 1 (BGB324) used in the activity measurement is as follows: [ka]
[0152] The specific structure of positive drug 2 (TP0903) is as follows: [ka]
[0153] The above compounds were purchased from Shanghai Shenghong Biotechnology Co., Ltd.
[0154] (1) AXL kinase inhibitory activity 1. Experimental process a) Preparation and addition of AXL enzyme (Carna, 08-107): 33.33 ng / μL of AXL enzyme was diluted to 0.027 ng / μL (1.67×, final concentration = 0.016 ng / μL) using 1× enzyme buffer (200 μL of enzyme buffer kinase 5×, 10 μL of 500 mM MgCl2, 10 μL of 100 mM DTT, 6.26 μL of 2500 nM SEB, and 773.75 μL of H2O to prepare 1 mL 1× enzyme buffer). 6 μL of enzyme solution with a final concentration of 1.67 times was added to each of the compound wells and positive control wells using a BioTek (MultiFloFX) automated dispenser. 6 μL of 1× enzyme buffer was added to the negative control wells.
[0155] b) Compound preparation and addition: The compounds and positive drugs prepared in Example 1 were diluted from 10 mM to 100 μM using DSMO and titrated using a compound titrator (Tecan, D300e). The titrator automatically injected the desired concentration into each well, starting with 1 μM at the first concentration and diluting in a 1 / 2 logarithmic gradient for a total of 8 concentrations. Centrifuge at 2500 rpm for 30 seconds and incubate at room temperature for 15 minutes.
[0156] c) Preparation and addition of ATP and substrate: ATP (Sigma, A7699) was diluted from 10 mM to 75 μM (5×) with 1× enzyme buffer to a final concentration of 15 μM. Substrate TK Substrate 3-biotin (Cisbio, 61TK0BLC) was diluted from 500 μM to 5 μM (5×) with 1× enzyme buffer to a final concentration of 1 μM. ATP was mixed with the substrate in equal volumes and 4 μL was added to each well using a BioTek automated dispenser. The mixture was centrifuged at 2500 rpm for 30 seconds and reacted at 25°C for 45 minutes.
[0157] d) Preparation and addition of detection reagent: Streptavidin-XL665 (Cisbio, 610SAXLG) was diluted from 16.67μM to 250nM (4x) with HTRFK in EASE detection buffer (cisbio) to a final concentration of 62.5nM. TK Antibody-Cryptate (Cisbio) was diluted from 100x to 5x with HTRF KinEASE detection buffer (cisbio) to a final concentration of 1x. XL665 was mixed with the antibody in equal volumes, and 10μL was added to each well using a BioTek automatic dispenser, centrifuged at 2500rpm for 30 seconds, and reacted at 25℃ for 1 hour. After the reaction was completed, the reaction was detected using a multifunctional plate reader HTRF.
[0158] 2. Data Analysis IC of AXL kinase inhibition by compounds 50 Values were obtained by fitting quantitative effect curves using the log(inhibitor) vs. response-variable slope of GraphPad Prism5 software. The inhibition rate was calculated using the following formula.
number
[0159] 3. The details of the experimental results are shown in the table below. [Table 9]
[0160] (2) Cell proliferation inhibition measurement of compounds 1. Experimental process MV-4-11 (human myelomonocytic leukemia cell line, medium: IMDM + 10% fetal bovine serum) was purchased from Nanjing Kebai Biotechnology Co., Ltd. and cultured in an incubator at 37℃ and 5% CO2. Cells in the logarithmic growth phase were harvested and inoculated into 96-well plates at cell densities of 8000 cells / well, 6000 cells / well, 5000 cells / well, 4000 cells / well, and 3000 cells / well, respectively, and a blank control group was set up at the same time.
[0161] Test compounds and positive drugs were dissolved in dimethyl sulfoxide to prepare 10 mM stock solutions and stored long term in a refrigerator at -80°C. 24 hours after plating the cells, the 10 mM compound stock solutions were diluted with dimethyl sulfoxide to obtain 200x working solutions (maximum concentration 200μM or 2000μM, 3x gradient, total of 10 concentrations), 3μL per concentration was added to 197μL complete medium and diluted to obtain 3x working solutions, then 50μL of working solution was added to 100μL cell culture medium (final concentration of dimethyl sulfoxide was 0.5%, v / v) and two duplicate wells were set up for each concentration. After 72 hours of treatment, 50 μL of CellTiter-Glo (registered trademark) (purchased from Promega) was added to each well, and the fluorescent signal was measured using Enbision (PerkinElmer) according to the procedure in the instruction manual. The IC value of cell proliferation inhibition by the compound was calculated by fitting the quantitative effect curve using GraphPad Prism 5 software log (inhibitor) vs. response-variable slope. 50 Got the value.
[0162] Inhibition rate calculation formula:
number
[0163] Where: Test substance signal value: average value of the fluorescence signal of the cell + medium + compound group; Blank group signal value: average value of the fluorescent signal in the medium group (containing 0.5% DMSO); Signal value of the negative control group: average value of the fluorescent signal of the cells + medium group (containing 0.5% DMSO).
[0164] 2. Experimental Results IC of the compound of Example 1 for antiproliferative activity in MV4-11 cells 50 (MV4-11, nM) was 6.97.
[0165] (3) In vivo MV4-11 efficacy of the compound The in vivo tumor growth inhibitory effects of test compounds and positive drugs were tested using a nude mouse transplantation model of human acute monocytic leukemia cells MV4-11.
[0166] 1. Creating the Mouse Model Logarithmic growth phase MV4-11 cells were harvested, counted, and resuspended at a cell concentration of 7.0 × 10 7 The resulting solution was subcutaneously injected into the right front axilla of nude mice, with each animal receiving 200 mL (14 × 10 6 The MV4-11 tumor model was created by inoculating 100 to 300 mm2 of 1000 cells / animal. 3 Once the tumors reached the target size, mice in good health and with similar tumor volumes were selected.
[0167] 2. Compound Preparation The compound and positive drug were vortexed in an appropriate solvent and sonicated to completely dissolve the compound, then an appropriate amount of citrate buffer was slowly added and vortexed to mix the liquid uniformly, and the solution was diluted to 0.1, 0.5, or 1 mg mL -1 Thus, a formulation for administration having a concentration of Solvent control group: PEG400 & citrate buffer (20:80, v:v).
[0168] 3. Animal Grouping and Drug Administration The model mice were randomly divided into groups (n=6), and the relevant compounds and positive drugs were administered on the day of grouping. After 21 days, the tumor volume of the vehicle control group was 2000 mm 3 The experiment was terminated when the drug concentration reached 10 mL kg -1 The compounds and positive drugs were orally administered once a day. After the start of the experiment, tumor diameter and body weight were measured twice a week, and tumor volume was calculated.
[0169] 4. Data Analysis The formula for calculating tumor volume (TV) is: tumor volume (mm 3 )=l×w 2 In the formula, l is the long axis of the tumor (mm), and w is the short axis of the tumor (mm).
[0170] The formula for calculating relative tumor volume (RTV) is RTV=TV. t / TV initial Here, TV initial is the tumor volume measured at the time of administration in each group, and TV t is the tumor volume at each measurement during the administration period.
[0171] The formula for calculating the tumor growth inhibition rate (TGI) (%) is TGI = 100% × [1-(TV t(T) -TV initial(T) ) / (TV t(C) -TV initial(C) )], where TV t(T) indicates tumor volume per measurement in the treatment group, and TV initial(T) indicates the tumor volume in the treatment group when administered in groups, and TV t(C) indicates tumor volume per measurement in the vehicle control group, and TV initial(C) indicates tumor volume in the solvent control group when administered in separate groups.
[0172] The formula for calculating the relative tumor proliferation rate (%T / C) is %T / C = 100% × (RTV T / RTV C ), where RTV T indicates treatment group RTV, RTV C indicates the solvent control group RTV.
[0173] The experimental data were calculated and relevant statistics were processed using Microsoft Office Excel 2007 software.
[0174] 5.The experimental results are as follows: [Table 10]
[0175] Note: The experimental data in the table are relevant data obtained at the end of the experiment (end of the experiment after 21 days or when the tumor volume of the vehicle control group reached 2000 mm). 3 is defined as when it reaches (whichever index is reached first).
[0176] (4) Pharmacokinetic study of compounds in ICR mice 1. Preparation of oral formulation of compound Compounds were prepared as 10 mg / mL stock solutions in DMSO. Mixed solvent preparation: Tween 80: PEG 400: Water = 1:9:90 (v / v / v) 450 μL of DMSO stock solution of each compound with a concentration of 10 mg / mL was accurately aspirated into a glass bottle, and appropriate amounts of DMSO and mixed solvent were added so that the solvent ratio in the final formulation was DMSO:mixed solvent (v / v) = 10:90. The mixture was vortexed (or sonicated) to disperse uniformly, and 4.5 mL of test solution for administration with a concentration of 1 mg / mL was obtained.
[0177] 2. Test Protocol Six male ICR mice aged 6 to 10 weeks (obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd.) were prepared for each group, and were fasted overnight and fed 4 hours after drug administration. On the day of the experiment, the mice were administered 10 mg x kg -1Each drug was orally administered. Approximately 100 μL of blood was collected from the mouse's orbit at 0, 5, 15, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h after drug administration and placed in an EDTA-K2 anticoagulant tube. Whole blood samples were centrifuged at 1500-1600 g for 10 min, and the separated plasma was stored in a refrigerator at -40 to -20°C and used for the analysis of biological samples. Blood drug concentrations were measured by LC-MS / MS.
[0178] 3. Data Analysis and Results Pharmacokinetic parameters were calculated using the non-atrial model in Pharsight Phoenix 7.0 and the results are detailed in the table below. [Table 11]
[0179] Example 3: Preparation of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide mono-p-toluenesulfonate monohydrate (compound of formula II) crystalline form B [ka]
[0180] A 500 mL double-glazed jacketed reactor was charged with p-toluenesulfonic acid monohydrate (6.87 g) and 99% isopropanol-water (volume ratio, 140 mL), and the temperature was raised to 70° C. with mechanical stirring to dissolve until clear. (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide (compound of formula IV, prepared according to the method of Example 1) (20 g) was dissolved in 99% isopropanol-water (volume ratio, 60 mL) and added dropwise to the reactor over about 15 minutes. After stirring for several minutes, a large solid precipitated in the reactor, and stirring was continued for about 15 minutes. The reaction system was cooled to 60°C, and methyl tert-butyl ether (200 mL) was added to the reactor. After the addition, the mixture was stirred at 60°C for 1 hour. After aging, the reaction system was cooled to 20°C, and stirring aging was continued for 1 hour. After aging, the mixture was suction filtered, and the wet filter cake was dried under vacuum at 40°C for 15 hours to obtain 23.67 g (yield: 88.3%) of mono-p-toluenesulfonate monohydrate crystal form B of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide in the form of yellow solid powder.
[0181] 1HNMR(400MHz,DMSO-d6):11.11(s,1H);9.40(br,1H);9.37(s,1H);8.56~8.54(m,1H),8.19(s,1H),7.5 6(dd,J=14,2Hz,1H);7.50~7.45(m,4H);7.37(dd,J=8.2,2.2Hz,1H);7.11(d,J=7.9,2H);7.04(d,J=8. 2,1H);4.44(s,2H);3.48(s,3H);3.33(s,3H);3.15(s,2H);2.82~2.62(m,4H);2.32(s,2H);2.29(s,3H) );1.98(s,2H);1.85~1.83(m,2H);1.81(d,J=2.4Hz,3H);1.77(d,J=2.4Hz,3H);1.39(q,J=11.9Hz,2H.
[0182] Its powder X-ray diffraction data is detailed in Table 12 and Figure 1. The DSC graph shows endothermic peaks at 90°C and 200°C, and the details are shown in Figure 2. The TGA graph shows a weight loss of 2.4% from 25 to 150°C, and the specific data is shown in Figure 3. The FT-IR graph is shown in Figure 4, the FT-Raman graph in Figure 5, and the DVS graph in Figure 6. [Table 12-1] [Table 12-2]
[0183] Example 4: Preparation of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide mono-p-toluenesulfonate monohydrate (compound of formula II) crystalline form B In a 50 mL glass bottle, (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide (compound of formula IV, 2.34 g), p-toluenesulfonate monohydrate (0.80 g) and ethanol (11.7 mL) were dissolved at room temperature with magnetic stirring until clear. After about 10 minutes, a large solid precipitated. Stirring was continued for about 30 minutes. Isopropyl acetate (11.7 mL) was added to the glass bottle. After the addition, the mixture was aged at room temperature for about 30 minutes with stirring. After aging was completed, isopropyl acetate (11.7 mL) was added to the glass bottle and aging was continued for about 1.5 hours. After completion of aging, suction filtration was performed and the wet filter cake was dried under vacuum at 40° C. for 24 hours to obtain 2.35 g (yield: 74.8%) of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide mono-p-toluenesulfonate monohydrate crystal form B in the form of pale yellow solid powder.
[0184] Example 5: Preparation of single crystals of crystalline form B of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide mono-p-toluenesulfonate monohydrate (compound of formula II) Single crystal cultivation method: A sample of crystalline form B monohydrate was dissolved in 95% ethanol-water to prepare a 9.1 mg / mL suspension, which was then heated to 50-60°C until clear. After filtration, the solution was cooled to room temperature to precipitate crystals, and a thin, needle-like single crystal was obtained. The crystal parameters and structural data are shown in the table below. [Table 13]
[0185] Analysis of the X-ray single crystal diffraction data indicated that crystalline form B was a monohydrate.
[0186] Example 6: Preparation of crystalline form C of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide mono-p-toluenesulfonate sesquihydrate (compound of formula III) Monohydrate form B was dissolved in water to prepare a suspension with a concentration of about 3 mg / mL, which was then heated to 50-60°C until clear, filtered, and cooled to room temperature to precipitate crystals, obtaining sesquihydrate form C as elongated, needle-like single crystals. The XRPD graph is shown in Figure 7, and the data details are shown in Table 14. [Table 14]
[0187] The crystal parameters and structural data of single crystal XRD of crystalline form C are shown in Table 15. [Table 15-1] [Table 15-2]
[0188] From the above single crystal structural analysis data, it was confirmed that crystalline form C is a sesquihydrate.
[0189] Example 7: Solubility measurements Test method for the solubility of mono-p-toluenesulfonate monohydrate crystalline form B of compound of formula IV in water Approximately 0.5 g of crystalline form B was precisely weighed, water was added dropwise to it, and the amount of solvent added and the state of dissolution of crystalline form B were recorded. When crystalline form B was completely dissolved until it was clear, the amount of solvent added was recorded and the critical saturation solubility was calculated. If crystalline form B could not be dissolved until it was clear even after adding 50 mL or more of solvent, a sample was taken and centrifuged to measure the saturation solubility.
[0190] Test method for the solubility of mono-p-toluenesulfonic acid monohydrate crystal form B of compound of formula IV at various pH values Approximately 0.2 g of crystalline form B was precisely weighed, and the solvent was added dropwise to it, and the amount of solvent added and the state of dissolution of crystalline form B were recorded. When crystalline form B was completely dissolved until it was clear, the amount of solvent added was recorded and the critical saturation solubility was calculated. If crystalline form B could not be dissolved until it was clear even after adding more than 50 mL of solvent, a sample was taken and centrifuged to measure the saturation solubility. The solubility of mono-p-toluenesulfonic acid monohydrate crystalline form B of compound of formula IV is shown in the table below. [Table 16]
[0191] Example 8: Preparation of crystalline form A of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide (compound of formula IV) 200 mg of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide prepared according to the method of Example 1 and 2 mL of purified water were added to a 3 mL glass bottle and magnetically stirred at room temperature for 6 hours. The sample was then centrifuged and the wet sample was dried under reduced pressure at 40° C. for 21 hours to obtain 176 mg of crystalline form A (yield 88.0%). The details of the XRPD graph are shown in FIG. 8 and the details of the powder X-ray diffraction graph data are shown in Table 17. [Table 17]
[0192] Example 9: Study of the physical and chemical stability of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide crystalline forms The stability of the free base crystal form A of the compound of formula IV and the mono-p-toluenesulfonate crystal form B of the compound of formula IV were tested under conditions of 40℃ / 75%RH, 60℃, 75%RH, 92.5%RH and light, respectively. The specific test method was based on the requirements of the 9001 guideline on stability testing of raw materials and preparations in the Four General Rules of the Chinese Pharmacopoeia, 2020 edition. The physical and chemical stability of the samples were measured by XRPD and HPLC. The specific results are shown in the table below. [Table 18] [Table 19]
[0193] Example 10: Preparation of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide (compound of formula IV) other acid salts and crystalline forms Approximately 50 mg of compound of formula IV (prepared according to the method of Example 1) and 1.05 equivalents of acid (hydrochloric acid, the molar ratio of acid to compound of formula IV was set to 2.10) were taken separately and added to 1 mL of solvent and stirred at room temperature for 2 days. Crystallization was attempted by slowly evaporating the resulting clear solution with stirring at 5°C, and the solid was separated by centrifugation and dried at 40°C under blowing or reduced pressure for 2-5 hours before being used for XRPD characterization. [Table 20-1] [Table 20-2] [Table 20-3]
[0194] Specifically, the methanesulfonate salt of the compound of formula IV was prepared as follows. Approximately 50 mg of the compound of formula IV and 1.05 equivalents of methanesulfonic acid were taken separately, added to 1 mL of toluene, and stirred at room temperature for 2 days. The resulting liquid was slowly evaporated with stirring at 5°C to crystallize. The solid was separated by centrifugation and dried under reduced pressure at 40°C for 2-5 hours to obtain the methanesulfonate salt crystal form of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide. Its XRPD is shown in Figure 9.
[0195] The X-ray powder diffraction (XRPD) spectra of the hydrochloride, dihydrochloride, phosphate, hippurate, sulfate, hydrobromide, benzenesulfonate, oxalate, fumarate, and citrate salts of the compound of formula IV are shown in Figures 10-19, respectively.
[0196] Example 11: Preparation of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide mono-p-toluenesulfonate salt or its hydrate (compound of formula I) The crystalline form B prepared in Example 4 was dried under reduced pressure at 40°C for 16 hours to prepare mono-p-toluenesulfonate (X=0-1) hydrate of compound of formula I, and samples were taken for XRPD detection, and their powder X-ray diffraction graphs are shown in detail in Figure 20. [ka]
Claims
1. Mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide or a hydrate thereof.
2. The mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide according to claim 1 , having the specific structure represented by formula I, or a hydrate thereof. 【Chemistry 1】 (wherein X=0 to 2, and further, X=0 to 1 or 1.5; Further, X is 0, 0.25, 0.5, 0.7, 1, 1.25, 1.5 or 1.
75.
3. In its powder X-ray diffraction graph, it has diffraction peaks at 2θ of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 13.2°±0.2° and 21.8°±0.2°, Furthermore, in its powder X-ray diffraction graph, it has diffraction peaks at 2θ of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 21.8°±0.2° and 22.6°±0.2°; Furthermore, in its powder X-ray diffraction graph, it has diffraction peaks at 2θ of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 18.7°±0.2°, 19.4°±0.2°, 19.7°±0.2°, 21.8°±0.2°, 22.6°±0.2° and 29.4°±0.2°; Furthermore, in the powder X-ray diffraction graph, 2θ is 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 12.3°±0.2°, 12.4°±0.2°, 12.6°±0.2°, 13.2°±0.2°, 14.1°±0.2°, 15.2°±0.2°, 15.9°±0.2°, 16.7°±0.2° , 17.1°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 18.7°±0.2°, 19.0°±0.2°, 19.4°±0.2°, 19.7°±0.2°, 21.1°±0.2°, 21.8°±0.2°, 22.6°±0.2°, 23.3°±0.2°, 23.7°±0.2°, 24.1°±0.2°, 24.4°±0. Diffraction peaks at 2°, 24.7°±0.2°, 25.1°±0.2°, 26.2°±0.2°, 26.6°±0.2°, 27.0°±0.2°, 27.7°±0.2°, 28.0°±0.2°, 28.3°±0.2°, 28.7°±0.2°, 28.8°±0.2°, 29.4°±0.2°, 30.2°±0.2° and 33.9°±0.2°.
4. The mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide in a crystalline form, having a moiety of 5,5-dichloro-2,6-dichloro-2,7 ...
4. The mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide according to claim 1 , wherein the monohydrate has the specific structure shown in formula II, or a hydrate thereof. 【Chemistry 2】
5. In a powder X-ray diffraction graph of the crystalline form of the monohydrate, the crystalline form has diffraction peaks at 2θ of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 13.2°±0.2°, and 21.8°±0.2°; Furthermore, in its powder X-ray diffraction graph, it has diffraction peaks at 2θ of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 21.8°±0.2° and 22.6°±0.2°; Furthermore, in its powder X-ray diffraction graph, it has diffraction peaks at 2θ of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 18.7°±0.2°, 19.4°±0.2°, 19.7°±0.2°, 21.8°±0.2°, 22.6°±0.2° and 29.4°±0.2°; Further, in the powder X-ray diffraction graph, 2θ is 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 12.3°±0.2°, 12.4°±0.2°, 12.6°±0.2°, 13.2°±0.2°, 14.1°±0.2°, 15.2°±0.2°, 15.9°±0.2°, 16.7°±0.2°, 17.1°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 18.7°±0.2°, 19.0°±0.2°, 19.4°±0.2°, 19.7°±0.2°, having diffraction peaks at 21.1°±0.2°, 21.8°±0.2°, 22.6°±0.2°, 23.3°±0.2°, 23.7°±0.2°, 24.1°±0.2°, 24.4°±0.2°, 24.7°±0.2°, 25.1°±0.2°, 26.2°±0.2°, 26.6°±0.2°, 27.0°±0.2°, 27.7°±0.2°, 28.0°±0.2°, 28.3°±0.2°, 28.7°±0.2°, 28.8°±0.2°, 29.4°±0.2°, 30.2°±0.2° and 33.9°±0.2°; The mono-p-toluenesulfonate or hydrate thereof according to claim 4, further having a powder X-ray diffraction pattern expressed in terms of 2θ angles as shown in FIG.
6. The mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide according to claim 1 , wherein the sesquihydrate has the specific structure shown in Formula III, or a hydrate thereof. 【Chemistry 3】
7. In the powder X-ray diffraction graph of the crystalline form of the sesquihydrate, the diffraction peaks are at 2θ of 13.4°±0.2°, 18.4°±0.2°, 19.3°±0.2°, 19.8°±0.2°, and 21.8°±0.2°; Furthermore, in its powder X-ray diffraction graph, it has diffraction peaks at 2θ of 12.1°±0.2°, 13.4°±0.2°, 15.0°±0.2°, 16.9°±0.2°, 18.4°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 21.8°±0.2°, 23.6°±0.2° and 24.3°±0.2°; Furthermore, in its powder X-ray diffraction graph, it has diffraction peaks at 2θ of 6.0°±0.2°, 10.8°±0.2°, 12.1°±0.2°, 13.4°±0.2°, 15.0°±0.2°, 16.9°±0.2°, 18.4°±0.2°, 19.0°±0.2°, 19.3°±0.2°, 19.8°±0.2°, 20.9°±0.2°, 21.8°±0.2°, 23.2°±0.2°, 23.6°±0.2°, 24.3°±0.2°, 25.5°±0.2° and 26.6°±0.2°; The mono-p-toluenesulfonate or hydrate thereof according to claim 6, further comprising a powder X-ray diffraction pattern expressed in terms of 2θ angles, as shown in FIG.
8. 2. A process for preparing the mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide or a hydrate thereof according to claim 1, comprising forming a salt of a compound of formula IV with p-toluenesulfonic acid, wherein the compound of formula IV has the following structure: 【Chemistry 4】
9. A crystalline composition, comprising the mono-p-toluenesulfonic acid salt or its hydrate according to any one of claims 1 to 7, or the mono-p-toluenesulfonic acid salt or its hydrate prepared as described in claim 8, in an amount of 50% by weight or more of the crystalline composition; Further, 80% by weight or more of the crystalline composition, Further, 90% by weight or more of the crystalline composition, Further, the crystalline composition accounts for 95% by weight or more of the crystalline composition.
10. A pharmaceutical composition of mono-p-toluenesulfonate salt of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide, comprising the mono-p-toluenesulfonate salt or a hydrate thereof according to any one of claims 1 to 7, or the mono-p-toluenesulfonate salt or a hydrate thereof prepared as described in claim 8, or the crystalline form composition according to claim 9.
11. Use of the mono-p-toluenesulfonate salt or hydrate of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide according to any one of claims 1 to 7, or the mono-p-toluenesulfonate salt or hydrate prepared as described in claim 8, or the crystalline form composition according to claim 9, or the pharmaceutical composition according to claim 10, in the preparation of a medicament for use in the prevention and / or treatment of a disease or condition mediated by AXL kinase.
Citation Information
Patent Citations
Pyrimidine derivatives
JP2010533700A
Compositions and methods for inhibiting the JAK pathway
JP2012515793A
Anilinopyrimidine AS as hematopoietic progenitor kinase 1 (HPK1) inhibitors
JP2020503271A
Pyrimidine-based compounds as AXL inhibitors
JP2023527242A
Heterocyclic compounds as AXL inhibitors
US20170137426A1
